Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 541

Sort by

Sort Order Select

Journal Articles

Statistical Learning Approaches for Predicting Lisocabtagene Maraleucel (liso-cel) Drug Product Composition from Donor-Selected Material Composition

Yue Jiang, PhD, Afshin Mashadi-Hossein, MSc, Rachel Yost, Jeffrey Teoh, PhD, Ryan P. Larson, PhD, Ronald J. Hause, PhD

Blood (2019) 134 (Supplement_1): 591.

https://doi.org/10.1182/blood-2019-125801

Published: 2019

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Jeffrey Teoh, PhD, Timothy G. Johnstone, PhD, Brian Christin, BS, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, MD, Tina Albertson, MD, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, PhD, Ryan P. Larson, PhD

Blood (2019) 134 (Supplement_1): 593.

https://doi.org/10.1182/blood-2019-127150

Published: 2019

Journal Articles

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Elise A. Chong, MD, James N. Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, David L. Porter, MD, Karen Dengel, BSN, RN, Don L. Siegel, MD PhD, Joan Gilmore, BS, Stefan K. Barta, MD MRCP, MS, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 594.

https://doi.org/10.1182/blood-2019-131078

Published: 2019

Journal Articles

Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

Bernhard Gentner, MD, Maria Ester Bernardo, MD PhD, Francesca Tucci, MD, Erika Zonari, PhD, Francesca Fumagalli, MD, Silvia Pontesilli, MD, Serena Acquati, PhD, Paolo Silvani, MD, Fabio Ciceri, MD, Attilio Rovelli, MD, Giancarlo La Marca, PhD, Rossella Parini, MD, Silvia Gregori, PhD, Eugenio Montini, PhD, Luigi Naldini, MD PhD, Alessandro Aiuti, MD PhD

Blood (2019) 134 (Supplement_1): 607.

https://doi.org/10.1182/blood-2019-128805

Published: 2019

Journal Articles

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Aspasia Stamatoullas, MD, Herv Ghesquieres, Lauriane Clement filliatre, MD, Philippe Quittet, MD, Franck Morschhauser, MD, Vincent Ribrag, MD, Veronique Edeline, MD, Pauline Brice

Blood (2019) 134 (Supplement_1): 132.

https://doi.org/10.1182/blood-2019-123925

Published: 2019

Journal Articles

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Blood (2019) 134 (Supplement_1): 353.

https://doi.org/10.1182/blood-2019-129835

Published: 2019

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Kirit M. Ardeshna, MBBChir, Maria A V Marzolini, Jane Norman, MD, Muhammad Al-Hajj, Simon Thomas, PhD, Jim Faulkner, Ekaterini Kotsopoulou, Martin Pule, MD, Vijay G R Peddareddigari, Nushmia Z Khokhar, Maud Jonnaert, PhD, Robert Chen, MD, Wendy Osborne, MD

Blood (2019) 134 (Supplement_1): 246.

https://doi.org/10.1182/blood-2019-122724

Published: 2019

Journal Articles

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Liora M Schultz, MD, Shabnum Patel, PhD, Sneha Ramakrishna, MD, Alice Bertaina, MD PhD, Neehar Bhatia, Jean Oak, MD PhD, Robbie G. Majzner, MD, Christina Baggott, RN, PhD, Kara L. Davis, DO, Crystal L. Mackall, MD, Steven A Feldman, PhD

Blood (2019) 134 (Supplement_1): 4471.

https://doi.org/10.1182/blood-2019-129436

Published: 2019

Journal Articles

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Autumn Diadamo, BS, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5174.

https://doi.org/10.1182/blood-2019-127277

Published: 2019

Journal Articles

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Agrima Mian, MBBS, MD, Wei Wei, MS, Allison M. Winter, MD, Jack Khouri, MD, Deepa Jagadeesh, MDMPH, Faiz Anwer, MD, Aaron T. Gerds, MD MS, Robert M. Dean, MD, Ronald Sobecks, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4452.

https://doi.org/10.1182/blood-2019-127087

Published: 2019

Journal Articles

Successful Treatment of Refractory Acute Lymphoblastic Leukemia with Tisagenlecleucel in the Setting of Life-Threatening Infection

Keith J August, MDMS, Terrie Flatt, DO,MA, Erin Marie Hall, MD, Doug Myers, MD

Blood (2019) 134 (Supplement_1): 5125.

https://doi.org/10.1182/blood-2019-130880

Published: 2019

Journal Articles

Tisagenlecleucel Manufacturing Feasibility in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia

Lamis K. Eldjerou, MD, Christopher Acker, BS, Damien Howick, MSc, Lee Clough, RN, Miriam Fuchs, MD PhD, Florence Salmon, PhD, Jennifer Willert, MD, Ranjan Tiwari, MSc, Mayo Pujols, MS, Matthew Robson, MD

Blood (2019) 134 (Supplement_1): 5066.

https://doi.org/10.1182/blood-2019-127346

Published: 2019

Journal Articles

A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

Hua Zhang, Lei Gao, Li Liu, Jishi Wang, PhD, Sanbin Wang, Li Gao, Cheng Zhang, MD PhD, Yao Liu, Peiyan Kong, Jia Liu, Jiaping He, Yu Han, Hua Shi, Yan He, Xun Ye, Yi Zhao, Wei Cao, Lianjun Shen, Xi Zhang

Blood (2019) 134 (Supplement_1): 3147.

https://doi.org/10.1182/blood-2019-131056

Published: 2019

Journal Articles

Fully Closed, Large-Scale, and Clinical Grade Cell Sorting of Hematopoietic Stem Cell (HSC)-Enriched CD90 + Cells for Transplantation and Gene Therapy

Stefan Radtke, PhD, Margaret Cui, Anai M Perez, Yan-Yi Chan, Stefanie Schmuck, BS, Andrew J Berger, PhD, Thomas Eunson, BSc, Hans-Peter Kiem, MD PhD

Blood (2019) 134 (Supplement_1): 3246.

https://doi.org/10.1182/blood-2019-125969

Published: 2019

Journal Articles

Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Jeffrey J. Bednarski, MD PhD, Clare Zimmerman, MD, Amanda F Cashen, MD, Sweta Desai, Mark Foster, Tim Schappe, BS, Ethan McClain, Michelle Becker-Hapak, BS, Melissa M Berrien-Elliott, PhD, Todd A Fehniger, MD PhD

Blood (2019) 134 (Supplement_1): 3307.

https://doi.org/10.1182/blood-2019-126982

Published: 2019

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Sunita Dwivedy Nasta, MD, Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Daniel J. Landsburg, MD, Elise A. Chong, MD, Stefan K. Barta, MD MRCP, MS, Noelle V. Frey, MD, James N. Gerson, MD, Amit Maity, MD PhD, John Plastaras, MD, David L. Porter, MD, Marco Ruella, MD, Jakub Svoboda, MD, Hatcher J. Ballard, BS, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 4108.

https://doi.org/10.1182/blood-2019-131399

Published: 2019

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Sattva S Neelapu, MD, Mohamed A Kharfan-Dabaja, MDMBA, Olalekan O. Oluwole, MBBS, MPH, Patel Krish, MD, Ran Reshef, MDMSc, Peter A. Riedell, MD, Parveen Shiraz, MD, Patrick J. Stiff, MD, Jose Villasboas, MD, Lovely Goyal, PhD, Jun Kawashima, Francesca Milletti, PhD, Edward Oliva, Jennifer Sun, MS, Javier Munoz, MD

Blood (2019) 134 (Supplement_1): 4093.

https://doi.org/10.1182/blood-2019-126369

Published: 2019

NARROW

Statistical Learning Approaches for Predicting Lisocabtagene Maraleucel (liso-cel) Drug Product Composition from Donor-Selected Material Composition

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II Study

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis

Successful Treatment of Refractory Acute Lymphoblastic Leukemia with Tisagenlecleucel in the Setting of Life-Threatening Infection

Tisagenlecleucel Manufacturing Feasibility in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia

A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

Fully Closed, Large-Scale, and Clinical Grade Cell Sorting of Hematopoietic Stem Cell (HSC)-Enriched CD90 + Cells for Transplantation and Gene Therapy

Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only